|Day's Range||32.23 - 32.49|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||22.73|
|Dividend & Yield||1.03 (3.17%)|
|1y Target Est||N/A|
Merck's Keytruda continued to gain share over immuno-oncology drugs from Bristol-Myers Squibb and Roche in May.
New data suggest that Novartis may have a drug that works similarly to Eylea but requires fewer monthly eye injections per year.
Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.